Table 2. Biomarkers data by diagnostic subgroup.
| CSF biomarkers and Fazekas | Controls | MCI | AD | p-value |
|---|---|---|---|---|
| Aβ1-42 pg/mL | 426.2 (165.2) | 423.2 (145.7) | 374.9 (123.6) | 0.535 |
| P-tau pg/mL | 46.8 (26.5) | 50.1 (32.4) | 48.3 (20.3) | 0.896 |
| T-tau pg/mL | 85.6 (50.3) | 107.1 (78.9) | 127.2 (79.3) | 0.179 |
| Aβ1-42/p-tau | 11.2 (6.3) | 11.7 (7.9) | 9.0 (5.8) | 0.462 |
| Fazekas (N) | Frequency (%) | |||
| 0 | 1 | 5 | 0 | 6 (7.7) |
| 1 | 17 | 20 | 7 | 44 (56.4) |
| 2 | 9 | 8 | 4 | 21 (26.9) |
| 3 | 3 | 1 | 3 | 7 (9.0) |
One-way ANOVA with Scheffé post-test;
* Chi-squared test. AD: Alzheimer's disease; MCI: mild cognitive impairment; CSF: cerebrospinal fluid; Aβ: amyloid-β; P-tau: phosphorylated tau; T-tau: total tau.